PSMA-PET Imaging for Prostate Cancer: Recent Advances and Key Updates : Episode 11

Video

July 4, 2023

Navigating Virtual Tumor Boards for Prostate Cancer PSMA-PET Imaging

Author(s):

Phillip Koo, MD,Michael S. Cookson, MD, MMHC

The panel shares their perspectives on the transition to virtual multidisciplinary tumor boards for patients with prostate cancer after the COVID-19 pandemic.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Risk Stratification of Patients with Prostate Cancer

EP: 2.Conventional Imaging for Prostate Cancer

EP: 3.Introduction to PSMA-Targeted PET Imaging

EP: 4.Approved PSMA-PET Imaging Tracer Options for Prostate Cancer

EP: 5.Practical Considerations for Selection of PSMA-PET Tracers

EP: 6.Impact of PSMA-Targeted Imaging Modalities on Management of Prostate Cancer

EP: 7.Overview of Available Clinical Guidelines on PSMA-PET Imaging in Prostate Cancer

EP: 8.Challenges of Implementing PSMA-Targeted PET Imaging in Prostate Cancer

EP: 9.Navigating and Overcoming Challenges of PSMA-PET Imaging Results Interpretation

EP: 10.Best Practices for Communication: A Multidisciplinary Perspective

EP: 11.Navigating Virtual Tumor Boards for Prostate Cancer PSMA-PET Imaging

EP: 12.Unmet Needs in Imaging for Patients With Prostate Cancer

EP: 13.PSMA-Based Imaging and Theranostics: A Summary of Current Paradigm Shifts and a Look to the Future

EP: 14.Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate Cancer

Related Videos

Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com

Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments

Study data point to gender disparities in oncology research citations

Study data point to gender disparities in oncology research citations

Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer

Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer

Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2

Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2

Betty Wang, MD, discusses studies from the 2025 EAU meeting

Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025

Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC

Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer

Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer

Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status

Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status

Dr Louise Kostos answers a question during a Zoom video interview

Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape

Dr Louise Kostos answers a question during a Zoom video interview

An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer

Related Content

Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com

May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

ARANOTE substudy highlights benefits of darolutamide in Black men

April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.

Dr. Murphy on increasing diversity in cancer clinical trials

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Stacy Loeb, MD, MSc, PhD | Credit: NYU Langone Health

April 26th 2025

TikTok, social media does more harm than good for prostate cancer education

Patrick Campbell

Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.

Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com

April 25th 2025

FDA clears AI-powered application for measuring prostate volume

Benjamin P. Saylor

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

Related Content

Prostate Cancer Viewpoints PSMA-PET Imaging for Prostate Cancer: Recent Advances and Key Updates

Prostate Cancer

|

|

PSMA-PET Imaging for Prostate Cancer: Recent Advances and Key Updates

Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com

May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

ARANOTE substudy highlights benefits of darolutamide in Black men

April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.

Dr. Murphy on increasing diversity in cancer clinical trials

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Stacy Loeb, MD, MSc, PhD | Credit: NYU Langone Health

April 26th 2025

TikTok, social media does more harm than good for prostate cancer education

Patrick Campbell

Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.

Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com

April 25th 2025

FDA clears AI-powered application for measuring prostate volume

Benjamin P. Saylor

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

Recent Content

Welcome to fabulous Las vegas Nevada sign with blur strip road b | Image Credit: © littlestocker - stock.adobe.com

AUA 2025 recap: Urologic oncology trials in progress

FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Lawmaker stands at podium | Image Credit: © ckybe - stock.adobe.com

Health policy expert highlights the importance of state-level urology advocacy

View More Recent Content

Terms and Conditions

Do not sell my Personnal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.